Download
https://www.ndtvprofit.com/research-reports/lupin-new-drugs-approvals-will-boost-future-prospects-axis-securities?utm_source=telegram&utm_medium=referral&utm_campaign=socialshare
Niche product approvals and a strong pipeline of new drugs could drive revenue/profit after tax compound annual growth rate by 10%/19.5% over FY24E-FY26E.
Share